Peptide Comparison

Compare peptides side-by-side.

Pick up to four peptides and compare mechanism, evidence grade, pharmacokinetics, administration and risk profile in a single view.

Selection · 3 / 4

Save & share

Save a set to reload it later on this device, or copy a share link to send the exact comparison to someone else.

Export comparison

Download the full side-by-side table as a landscape PDF for reading, or a CSV for spreadsheets and further analysis.

AI comparison summary

Biggest differences across ARA-290 (Cibinetide) · Retatrutide · BPC-157

Focused on evidence grade, pharmacokinetics, and risks/interactions — with inline citations to the primary references on each peptide page.

Click Generate summary to have AI highlight the biggest differences between the peptides you've selected.

ARA-290 (Cibinetide)

Grade BNeuroprotective

Overview

Evidence grade: Grade B
Category: Neuroprotective
Primary focus: Neuropathy, inflammation
Summary: Promising small-molecule peptide for diabetic neuropathy and sarcoidosis-related small fiber neuropathy. Phase II trials show improved nerve fiber density and reduced neuropathic pain without raising hematocrit.

Mechanism

Mechanism of action: 11-amino-acid peptide derived from erythropoietin's helix B. Binds the innate-repair receptor (a heterodimer of EPOR + βcR) to trigger tissue-protective and anti-inflammatory cascades without activating the hematopoietic EPO receptor.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~2 minutes systemic (sustained tissue receptor occupancy)
PK notes: ARA-290 (Cibinetide) is administered subcutaneous injection with an approximate systemic half-life of ~2 minutes systemic (sustained tissue receptor occupancy). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once daily) is designed to match receptor kinetics rather than plasma exposure. 11-amino-acid peptide derived from erythropoietin's helix B. Binds the innate-repair receptor (a heterodimer of EPOR + βcR) to trigger tissue-protective and anti-inflammatory cascades without activating the hematopoietic EPO receptor.

Administration

Typical dose: 4 mg
Frequency: Once daily
Cycle length: 28 days (typical trial protocol)
Timing: Morning, subcutaneous (abdominal site)
Protocol steps: Route: Subcutaneous injection. Typical starting dose 4 mg, Once daily.
Timing: Morning, subcutaneous (abdominal site) — keep it the same each dosing day to make effects legible.
Cycle length: 28 days (typical trial protocol). Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Improved corneal nerve fiber density in sarcoid neuropathy
Reduction in neuropathic pain scores (Phase II)
Anti-inflammatory effect without immunosuppression
No hematopoietic stimulation (unlike EPO)
Common stacks: Alpha-lipoic acid, B-complex with methylated B12, Omega-3

Risks

Side effects: Injection site irritation
Mild headache
Short-term safety profile favorable in completed trials
Contraindications: Active malignancy (limited data)
Pregnancy and lactation
Interactions: EPO / ESAs — Mechanistically distinct but caution if combined.
Legal status: Investigational drug; not approved for general human therapeutic use.

Retatrutide

Grade AMetabolic

Overview

Evidence grade: Grade A
Category: Metabolic
Primary focus: Triple GIP/GLP-1/glucagon agonist
Summary: Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.

Mechanism

Mechanism of action: First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.
Evidence explainer: Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.

Pharmacokinetics

Route: Subcutaneous injection
Half-life: ~6 days (supports once-weekly dosing)
PK notes: Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.

Administration

Typical dose: Titrated 2 mg → 4 mg → 8 mg → 12 mg
Frequency: Once weekly
Cycle length: Ongoing; weight regain occurs on cessation
Timing: Same day each week; any time of day
Protocol steps: Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly.
Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible.
Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: ~24% mean weight loss at 48 weeks (Phase II)
Marked improvements in HbA1c, blood pressure, ApoB and liver fat
Convenient once-weekly dosing
Likely best-in-class cardiometabolic profile
Common stacks: Creatine monohydrate, Whey protein, Vitamin D3 + K2

Risks

Side effects: Nausea, vomiting, diarrhea (especially during titration)
Injection site reactions
Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting
Theoretical pancreatitis and gallbladder risk (class effect)
Contraindications: Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia type 2
Pregnancy and lactation
Prior severe reaction to GLP-1 agonists
Interactions: Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required.
Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.
Legal status: Investigational; not yet FDA-approved. Currently available only via clinical trials.

BPC-157

Grade BRegenerative

Overview

Evidence grade: Grade B
Category: Regenerative
Primary focus: Tissue repair, gut integrity
Summary: Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.

Mechanism

Mechanism of action: Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Evidence explainer: Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.

Pharmacokinetics

Route: Subcutaneous or oral (gut-localized)
Half-life: ~4 hours (subcutaneous)
PK notes: BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.

Administration

Typical dose: 250–500 mcg
Frequency: 1–2× daily
Cycle length: 4–6 weeks on, 4 weeks off
Timing: Near site of injury or AM/PM fasted
Protocol steps: Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily.
Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible.
Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating.
Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.

Benefits

Reported benefits: Accelerated soft-tissue recovery in preclinical models
Gut barrier integrity and ulcer protection
Potential nervous system neuroprotection
Common stacks: TB-500, Collagen peptides, Vitamin C

Risks

Side effects: Generally well tolerated in animal studies
Injection site irritation
Long-term human safety unknown
Contraindications: Active malignancy (theoretical angiogenic concern)
Pregnancy and lactation
Interactions: Anticoagulants — Theoretical synergy via NO modulation — monitor.
VEGF inhibitors — Mechanistic opposition; avoid combination.
Legal status: Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

Attribute	ARA-290 (Cibinetide) Grade BNeuroprotective	Retatrutide Grade AMetabolic	BPC-157 Grade BRegenerative
Overview
Evidence grade	Grade B	Grade A	Grade B
Category	Neuroprotective	Metabolic	Regenerative
Primary focus	Neuropathy, inflammation	Triple GIP/GLP-1/glucagon agonist	Tissue repair, gut integrity
Summary	Promising small-molecule peptide for diabetic neuropathy and sarcoidosis-related small fiber neuropathy. Phase II trials show improved nerve fiber density and reduced neuropathic pain without raising hematocrit.	Phase II trial results showed ~24% mean weight loss at 48 weeks at the 12 mg dose — markedly exceeding tirzepatide and prior GLP-1 monotherapies. Currently in Phase III; not yet FDA-approved but expected to be a landmark obesity and metabolic therapy.	Studied extensively in animal models for tendon, ligament, muscle, and gut mucosal healing. Human evidence is limited to small clinical observations.
Mechanism
Mechanism of action	11-amino-acid peptide derived from erythropoietin's helix B. Binds the innate-repair receptor (a heterodimer of EPOR + βcR) to trigger tissue-protective and anti-inflammatory cascades without activating the hematopoietic EPO receptor.	First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.	Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Evidence explainer	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.	Grade A — supported by multiple randomised human trials or an approved regulatory indication. Mechanism, dosing and safety are well characterised in humans.	Grade B — supported by preclinical evidence plus at least one small human trial, pharmacokinetic study, or strong translational rationale. Human long-term safety is incomplete.
Pharmacokinetics
Route	Subcutaneous injection	Subcutaneous injection	Subcutaneous or oral (gut-localized)
Half-life	~2 minutes systemic (sustained tissue receptor occupancy)	~6 days (supports once-weekly dosing)	~4 hours (subcutaneous)
PK notes	ARA-290 (Cibinetide) is administered subcutaneous injection with an approximate systemic half-life of ~2 minutes systemic (sustained tissue receptor occupancy). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once daily) is designed to match receptor kinetics rather than plasma exposure. 11-amino-acid peptide derived from erythropoietin's helix B. Binds the innate-repair receptor (a heterodimer of EPOR + βcR) to trigger tissue-protective and anti-inflammatory cascades without activating the hematopoietic EPO receptor.	Retatrutide is administered subcutaneous injection with an approximate systemic half-life of ~6 days (supports once-weekly dosing). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (Once weekly) is designed to match receptor kinetics rather than plasma exposure. First-in-class triple agonist of GIP, GLP-1, and glucagon receptors. The GLP-1 and GIP arms drive glucose-dependent insulin secretion and satiety; the glucagon arm increases energy expenditure — producing the largest weight-loss effect of any incretin to date.	BPC-157 is administered subcutaneous or oral (gut-localized) with an approximate systemic half-life of ~4 hours (subcutaneous). Steady-state and tissue-level effects can outlast plasma concentration, which is why dosing frequency (1–2× daily) is designed to match receptor kinetics rather than plasma exposure. Pentadecapeptide derived from gastric protective protein BPC. Upregulates VEGFR2, modulates nitric oxide synthesis, and accelerates angiogenesis and fibroblast migration.
Administration
Typical dose	4 mg	Titrated 2 mg → 4 mg → 8 mg → 12 mg	250–500 mcg
Frequency	Once daily	Once weekly	1–2× daily
Cycle length	28 days (typical trial protocol)	Ongoing; weight regain occurs on cessation	4–6 weeks on, 4 weeks off
Timing	Morning, subcutaneous (abdominal site)	Same day each week; any time of day	Near site of injury or AM/PM fasted
Protocol steps	Route: Subcutaneous injection. Typical starting dose 4 mg, Once daily. Timing: Morning, subcutaneous (abdominal site) — keep it the same each dosing day to make effects legible. Cycle length: 28 days (typical trial protocol). Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous injection. Typical starting dose Titrated 2 mg → 4 mg → 8 mg → 12 mg, Once weekly. Timing: Same day each week; any time of day — keep it the same each dosing day to make effects legible. Cycle length: Ongoing; weight regain occurs on cessation. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.	Route: Subcutaneous or oral (gut-localized). Typical starting dose 250–500 mcg, 1–2× daily. Timing: Near site of injury or AM/PM fasted — keep it the same each dosing day to make effects legible. Cycle length: 4–6 weeks on, 4 weeks off. Reassess with bloods and symptom logs before repeating. Rotate sites across the abdomen (avoiding a 2 cm radius around the navel), outer thighs and flanks. Never inject through a bruise or mole.
Benefits
Reported benefits	Improved corneal nerve fiber density in sarcoid neuropathy Reduction in neuropathic pain scores (Phase II) Anti-inflammatory effect without immunosuppression No hematopoietic stimulation (unlike EPO)	~24% mean weight loss at 48 weeks (Phase II) Marked improvements in HbA1c, blood pressure, ApoB and liver fat Convenient once-weekly dosing Likely best-in-class cardiometabolic profile	Accelerated soft-tissue recovery in preclinical models Gut barrier integrity and ulcer protection Potential nervous system neuroprotection
Common stacks	Alpha-lipoic acid, B-complex with methylated B12, Omega-3	Creatine monohydrate, Whey protein, Vitamin D3 + K2	TB-500, Collagen peptides, Vitamin C
Risks
Side effects	Injection site irritation Mild headache Short-term safety profile favorable in completed trials	Nausea, vomiting, diarrhea (especially during titration) Injection site reactions Reduced appetite to the point of inadequate protein intake — pair with resistance training and protein targeting Theoretical pancreatitis and gallbladder risk (class effect)	Generally well tolerated in animal studies Injection site irritation Long-term human safety unknown
Contraindications	Active malignancy (limited data) Pregnancy and lactation	Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia type 2 Pregnancy and lactation Prior severe reaction to GLP-1 agonists	Active malignancy (theoretical angiogenic concern) Pregnancy and lactation
Interactions	EPO / ESAs — Mechanistically distinct but caution if combined.	Insulin and sulfonylureas — Risk of hypoglycemia — dose reduction usually required. Oral medications — Delayed gastric emptying may alter absorption; separate timing for narrow-therapeutic-index drugs.	Anticoagulants — Theoretical synergy via NO modulation — monitor. VEGF inhibitors — Mechanistic opposition; avoid combination.
Legal status	Investigational drug; not approved for general human therapeutic use.	Investigational; not yet FDA-approved. Currently available only via clinical trials.	Not approved by the FDA for human use. Sold as a research chemical in most jurisdictions.

← Back to all peptides